Radiopharm’s Breakthrough in Cancer Treatment
Company Announcements

Radiopharm’s Breakthrough in Cancer Treatment

Radiopharm Theranostics Limited (AU:RAD) has released an update.

Radiopharm Theranostics Limited reports significant progress in its radiopharmaceutical development, with encouraging data from RAD 301 and RAD 302 studies and a successful first patient dosing in a Phase 1 trial. Studies indicate potential for safer and more effective treatment of various carcinomas by targeting αvβ6-integrin. The company’s research, which includes a comparison study showing the superiority of RAD 301 over traditional methods, underlines the promise of its diagnostic and therapeutic agents for cancers like pancreatic and non-small cell lung cancer.

For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.


Price Change
S&P 500
Dow Jones
Nasdaq 100

Popular Articles